Jiangsu Nhwa Pharmaceutical Co., LTD
Symbool: 002262.SZ
SHZ
25.16
CNYMarktprijs vandaag
23.9060
Koers/Winst Verhouding
2.4589
Koers/Winst Groei Verhouding
25.35B
MRK Kapitalisatie
- 0.00%
DIV Rendement
Jiangsu Nhwa Pharmaceutical Co., LTD (002262-SZ) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 13635.22 | 3493.9 | 2984.2 | 2666 | |||||||||||||||||||
balance-sheet.row.short-term-investments | 5823.3 | 1335 | 1452 | 1058.4 | |||||||||||||||||||
balance-sheet.row.net-receivables | 4452.03 | 1091.7 | 937.3 | 757.7 | |||||||||||||||||||
balance-sheet.row.inventory | 2592.65 | 628.6 | 716.3 | 604.3 | |||||||||||||||||||
balance-sheet.row.other-current-assets | 94.68 | 40.3 | 12.6 | 15.1 | |||||||||||||||||||
balance-sheet.row.total-current-assets | 20774.58 | 5254.6 | 4650.4 | 4043.2 | |||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 5602.51 | 1539.5 | 1303.7 | 1158.3 | |||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.intangible-assets | 1083.69 | 276.2 | 223.8 | 167.5 | |||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 1083.69 | 276.2 | 223.8 | 167.5 | |||||||||||||||||||
balance-sheet.row.long-term-investments | -1914.2 | 157.3 | -1333.4 | -928 | |||||||||||||||||||
balance-sheet.row.tax-assets | 218.31 | 58.3 | 37.5 | 30.7 | |||||||||||||||||||
balance-sheet.row.other-non-current-assets | 3137.07 | 42.3 | 1599.7 | 1225.5 | |||||||||||||||||||
balance-sheet.row.total-non-current-assets | 8127.38 | 2073.6 | 1831.3 | 1654 | |||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.total-assets | 28901.96 | 7328.2 | 6481.7 | 5697.2 | |||||||||||||||||||
balance-sheet.row.account-payables | 1056.28 | 216.3 | 255.7 | 267.2 | |||||||||||||||||||
balance-sheet.row.short-term-debt | 380.84 | 136.8 | 50.6 | 63 | |||||||||||||||||||
balance-sheet.row.tax-payables | 542.85 | 84.1 | 143.6 | 125.7 | |||||||||||||||||||
balance-sheet.row.long-term-debt-total | 57.51 | 0.2 | 42.1 | 47.9 | |||||||||||||||||||
Deferred Revenue Non Current | 223.83 | 53.9 | 58 | 63.6 | |||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 40.67 | - | - | - | |||||||||||||||||||
balance-sheet.row.other-current-liab | 892.5 | 434.5 | 426.8 | 2.2 | |||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 329.6 | 50.2 | 103 | 111.5 | |||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 130.84 | 35.6 | 41.9 | 47.7 | |||||||||||||||||||
balance-sheet.row.total-liab | 3568.94 | 864.2 | 897 | 793.5 | |||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.common-stock | 4030.35 | 1007.6 | 1007.6 | 1007.6 | |||||||||||||||||||
balance-sheet.row.retained-earnings | 18875.34 | 4813 | 3978.4 | 3366.1 | |||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 2478.66 | 611.2 | 617.6 | 528.3 | |||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 21.03 | 2.3 | 18.7 | 18.7 | |||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 25405.37 | 6434.1 | 5622.2 | 4920.7 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 28901.96 | 7328.2 | 6481.7 | 5697.2 | |||||||||||||||||||
balance-sheet.row.minority-interest | -126.22 | -24 | -37.5 | -17 | |||||||||||||||||||
balance-sheet.row.total-equity | 25279.15 | 6410.1 | 5584.8 | 4903.7 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 28901.96 | - | - | - | |||||||||||||||||||
Total Investments | 3909.1 | 1492.3 | 118.6 | 130.4 | |||||||||||||||||||
balance-sheet.row.total-debt | 512.6 | 172.6 | 92.8 | 110.9 | |||||||||||||||||||
balance-sheet.row.net-debt | -7299.32 | -1986.4 | -1439.4 | -1496.7 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 1074.77 | 1036.9 | 880.4 | 798 | |||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 9.99 | 175.1 | 148.7 | 135.1 | |||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | -23.2 | -4 | 0.5 | |||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | -528.7 | 4 | 2.5 | |||||||||||||||||||
cash-flows.row.change-in-working-capital | -144.64 | -178.6 | -160.6 | -251.1 | |||||||||||||||||||
cash-flows.row.account-receivables | -199.06 | -199.1 | -155.3 | -122.9 | |||||||||||||||||||
cash-flows.row.inventory | 54.43 | 54.4 | -128.2 | -205.9 | |||||||||||||||||||
cash-flows.row.account-payables | 0 | -33.9 | 126.9 | 77.1 | |||||||||||||||||||
cash-flows.row.other-working-capital | -0.01 | 0 | -4 | 0.5 | |||||||||||||||||||
cash-flows.row.other-non-cash-items | -49.47 | 569 | -7.5 | 16.1 | |||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 890.65 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -348.07 | -374 | -327.8 | -206.1 | |||||||||||||||||||
cash-flows.row.acquisitions-net | 1.16 | 1.4 | 0.1 | 0.2 | |||||||||||||||||||
cash-flows.row.purchases-of-investments | -6453.5 | -6453.5 | -5527.5 | 0.3 | |||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 6518.29 | 6490.5 | 32.4 | 34.5 | |||||||||||||||||||
cash-flows.row.other-investing-activites | -313.73 | 0 | 5133.9 | -221.4 | |||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -595.85 | -335.6 | -688.9 | -392.5 | |||||||||||||||||||
cash-flows.row.debt-repayment | -65 | -25 | -48 | -38 | |||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0.5 | |||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | -0.5 | |||||||||||||||||||
cash-flows.row.dividends-paid | -206.97 | -201.5 | -202.7 | -102.3 | |||||||||||||||||||
cash-flows.row.other-financing-activites | 15.5 | -1.1 | 10 | 12.9 | |||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -215.97 | -210.2 | -240.8 | -127.4 | |||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.53 | 0.4 | 0.9 | -1.1 | |||||||||||||||||||
cash-flows.row.net-change-in-cash | 105.47 | 626.7 | -67.7 | 180 | |||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 7750.42 | 2158.9 | 1504.5 | 1572.2 | |||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 7644.95 | 1532.2 | 1572.2 | 1392.2 | |||||||||||||||||||
cash-flows.row.operating-cash-flow | 890.65 | 1050.5 | 861 | 701.1 | |||||||||||||||||||
cash-flows.row.capital-expenditure | -348.07 | -374 | -327.8 | -206.1 | |||||||||||||||||||
cash-flows.row.free-cash-flow | 542.57 | 676.6 | 533.3 | 495 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 5182.87 | 4973.5 | 4298.5 | 3935.7 | |||||||||||||||||||
income-statement-row.row.cost-of-revenue | 1479.99 | 1460.4 | 1020.5 | 897.3 | |||||||||||||||||||
income-statement-row.row.gross-profit | 3702.89 | 3513.1 | 3278.1 | 3038.3 | |||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||
income-statement-row.row.research-development | 571.7 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-general-administrative | 48.23 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1753.34 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-expenses | -22.02 | -25.5 | 159 | 126.2 | |||||||||||||||||||
income-statement-row.row.operating-expenses | 2586.71 | 2443.5 | 2312.2 | 2116 | |||||||||||||||||||
income-statement-row.row.cost-and-expenses | 4066.7 | 3903.9 | 3332.7 | 3013.3 | |||||||||||||||||||
income-statement-row.row.interest-income | 19.62 | 23.8 | 25.5 | 17.7 | |||||||||||||||||||
income-statement-row.row.interest-expense | 4.89 | 4.2 | 4.9 | 5.1 | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1753.34 | - | - | - | |||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 64.73 | 89.4 | -13.6 | -10.1 | |||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-operating-expenses | -22.02 | -25.5 | 159 | 126.2 | |||||||||||||||||||
income-statement-row.row.total-operating-expenses | 64.73 | 89.4 | -13.6 | -10.1 | |||||||||||||||||||
income-statement-row.row.interest-expense | 4.89 | 4.2 | 4.9 | 5.1 | |||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 89.4 | 175.1 | 159.4 | 173.2 | |||||||||||||||||||
income-statement-row.row.ebitda-caps | 1239.16 | - | - | - | |||||||||||||||||||
income-statement-row.row.operating-income | 1136.69 | 1069.6 | 1003.5 | 925.9 | |||||||||||||||||||
income-statement-row.row.income-before-tax | 1201.43 | 1159 | 989.9 | 915.8 | |||||||||||||||||||
income-statement-row.row.income-tax-expense | 136.17 | 134.4 | 109.5 | 117.8 | |||||||||||||||||||
income-statement-row.row.net-income | 1074.77 | 1036.9 | 900.7 | 797.8 |
Vaak gestelde vragen
Wat is Jiangsu Nhwa Pharmaceutical Co., LTD (002262.SZ) totale activa?
Jiangsu Nhwa Pharmaceutical Co., LTD (002262.SZ) totale activa is 7328195368.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is 2705694560.000.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.714.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is 0.207.
Wat is de totale omzet van de onderneming?
De totale opbrengst is 0.219.
Wat is Jiangsu Nhwa Pharmaceutical Co., LTD (002262.SZ) nettowinst (netto-inkomen)?
De nettowinst is 1036918058.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 172558561.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 2443472552.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 1635420861.000.